Literature DB >> 27260849

Surgical margins do not affect prognosis in high grade myxofibrosarcoma.

A Sambri1, G Bianchi2, A Righi3, C Ferrari4, D Donati5.   

Abstract

INTRODUCTION: Myxofibrosarcoma (MFS) is one of the most common soft tissue sarcomas (STS) in elderly patients and it primarily affects the extremities. The aim of this retrospective analysis is to understand the natural history of MFS and whether adequate treatment influence prognosis. PATIENTS AND METHODS: We reviewed 129 adult patients with primary, localized, FNCLCC grade 3 MFS of the extremities operated at Istituto Ortopedico Rizzoli, Bologna. Sarcoma specific survival (SS), local recurrence (LR) and distant metastasis (DM) were analyzed.
RESULTS: Among excised MFS (119), 106 (89.9%) had R0 margins, 13 (10.1%) R1 margins. No significant correlation between margins adequacy and tumor depth, location and size was found. Estimated SS was 73.2% at 5 years and 66.3% at 10 years, with a better SS in superficial MFS (p = 0.011). Local recurred MFS had a worse SS (p = 0.049). Local recurrence-free rate was 74.3% at 5 and 10 years. Even if not significant, a better outcome in term of LR was observed in superficial MFS and R0 margins. Distant metastasis-free survival was 75.6% at 5 years and 72.9% at 10 years, with a better outcome in superficial MFS (p = 0.012). DISCUSSION: Myxofibrosarcoma remain a debated entity with specific behavior features. Myxofibrosarcoma tends to local recur due to its infiltrative grow pattern making difficult to achieve "safe margins". To date, surgical margins as classified for other STS are not predictive of LR and patients' survival. Tumor grade and depth are still the most important prognostic factors.
Copyright © 2016 Elsevier Ltd and British Association of Surgical Oncology/European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Extremity sarcoma; Myxofibrosarcoma; Surgical margins

Mesh:

Year:  2016        PMID: 27260849     DOI: 10.1016/j.ejso.2016.05.015

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  14 in total

1.  Preoperative Planning Using Three-Dimensional Multimodality Imaging for Soft Tissue Sarcoma of the Axilla: A Pilot Study.

Authors:  Xiang Fang; Yan Xiong; Fang Yuan; Senlin Lei; Dechao Yuan; Yi Luo; Yong Zhou; Li Min; Wenli Zhang; Chongqi Tu; Hong Duan
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

2.  Soft-tissue reconstruction after soft-tissue sarcoma resection: the clinical outcomes of 24 patients.

Authors:  Hideo Hasegawa; Shinji Tsukamoto; Kanya Honoki; Takamasa Shimizu; Lorenzo Ferra; Costantino Errani; Spyros Sioutis; Andreas F Mavrogenis; Yasuhito Tanaka
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-02-20

3.  PROGNOSTIC FACTORS IN PATIENTS WITH APPENDICULAR MYXOFIBROSARCOMA.

Authors:  Juan Pablo Zumárraga; Felipe Augusto Ribeiro Batista; André Mathias Baptista; Marcelo Tadeu Caiero; Luis Pablo de la Rosa Martino; Olavo Pires de Camargo
Journal:  Acta Ortop Bras       Date:  2018       Impact factor: 0.513

4.  The value of C-reactive protein as an independent prognostic indicator for disease-specific survival in patients with soft tissue sarcoma: A meta-analysis.

Authors:  Xiaolin Wang; Song Liu; Xiaoli Zhao; Erhu Fang; Xiang Zhao
Journal:  PLoS One       Date:  2019-07-01       Impact factor: 3.240

5.  The Prognostic Role of Glasgow Prognostic Score and C-reactive Protein to Albumin Ratio for Sarcoma: A System Review and Meta-Analysis.

Authors:  Erhu Fang; Xiaolin Wang; Jiexiong Feng; Xiang Zhao
Journal:  Dis Markers       Date:  2020-01-07       Impact factor: 3.434

6.  Myxofibrosarcoma primary cultures: molecular and pharmacological profile.

Authors:  Alessandro De Vita; Federica Recine; Laura Mercatali; Giacomo Miserocchi; Chiara Liverani; Chiara Spadazzi; Roberto Casadei; Alberto Bongiovanni; Federica Pieri; Nada Riva; Dino Amadori; Toni Ibrahim
Journal:  Ther Adv Med Oncol       Date:  2017-10-28       Impact factor: 8.168

7.  Post-radiation sarcoma: A study by the Eastern Asian Musculoskeletal Oncology Group.

Authors:  Min Wook Joo; Yong Koo Kang; Koichi Ogura; Shintaro Iwata; June Hyuk Kim; Won Ju Jeong; Xiaohui Niu; Pramod S Chinder; Han Soo Kim; Sung Wook Seo; Yang-Guk Chung
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

8.  Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line.

Authors:  Giacomo Miserocchi; Alessandro De Vita; Laura Mercatali; Federica Recine; Chiara Liverani; Chiara Spadazzi; Federica Pieri; Nada Riva; Alberto Bongiovanni; Roberto Casadei; Valentina Fausti; Toni Ibrahim
Journal:  Cells       Date:  2018-10-25       Impact factor: 6.600

9.  High Recurrence Rate of Myxofibrosarcoma: The Effect of Radiotherapy Is Not Clear.

Authors:  Hjalmar Teurneau; Jacob Engellau; Iman Ghanei; Fredrik Vult von Steyern; Emelie Styring
Journal:  Sarcoma       Date:  2019-10-01

10.  Development and validation of a prognostic nomogram for predicting the overall survival of myxofibrosarcoma patients: a large population-based study.

Authors:  Shuai Cao; Jie Li; Jun Zhang; Haopeng Li
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.